phenytoin has been researched along with Alcohol Abuse in 70 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "To determine the effectiveness of IV phenytoin in the prevention of recurrent alcohol-related seizures during a six-hour observation period." | 9.07 | The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. ( Bernstein, E; D'Onofrio, G; Fish, SS; Harrison, PM; Hossack, RW; Pickens, L; Rathlev, NK, 1994) |
| "The efficacy of phenytoin in the prevention of alcohol withdrawal seizures was studied in rats." | 7.66 | Prevention of alcohol withdrawal seizures with phenytoin in rats. ( Chu, NS, 1981) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "To determine the effectiveness of IV phenytoin in the prevention of recurrent alcohol-related seizures during a six-hour observation period." | 5.07 | The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. ( Bernstein, E; D'Onofrio, G; Fish, SS; Harrison, PM; Hossack, RW; Pickens, L; Rathlev, NK, 1994) |
| "There is evidence that vitamin K-deficiency during human pregnancy can be caused by the therapeutic use of warfarin or phenytoin." | 3.68 | Binder's syndrome due to prenatal vitamin K deficiency: a theory of pathogenesis. ( Halliday, JL; Howe, AM; Lipson, AH; Sheffield, LJ; Webster, WS, 1992) |
| " In severely jaundiced patients (serum bilirubin concentrations greater than 140 mumol/l) a markedly decreased or absent uptake of 99mTc-EHIDA was observed." | 3.66 | The influence of bilirubin, alcohol and certain drugs on the kinetics of 99mTc-Diethyl IDA (EHIDA) in humans. ( Coenegracht, JM; Oei, TL; van Breda Vriesman, PJ, 1983) |
| "The efficacy of phenytoin in the prevention of alcohol withdrawal seizures was studied in rats." | 3.66 | Prevention of alcohol withdrawal seizures with phenytoin in rats. ( Chu, NS, 1981) |
| "Phenytoin has traditionally been used for both prophylaxis and acute treatment of alcohol withdrawal seizures." | 3.66 | Rational management of alcohol withdrawal seizures. ( Josephson, GW; Sabatier, HS, 1978) |
| "A 49-year-old female with chronic alcoholism and epilepsy, treated with phenytoin, began to convulse when treatment with disulfiram (an inhibitor of phenytoin metabolism) was discontinued." | 3.65 | Multiple drug interactions with phenytoin. ( Birkett, DJ; Chinwah, PM; Graham, GG; Hickie, JB; Wade, DN, 1977) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| " Drug was most often given on a fixed dosing schedule with additional medication "as needed" (52% of the programs)." | 1.29 | Alcohol withdrawal: a nationwide survey of inpatient treatment practices. ( Friedman, LS; Mayo-Smith, MF; Saitz, R, 1995) |
| "It is concluded that the groups with alcohol abuse who used hepatotoxic drugs showed a picture of cortical changes (wide transport sulci and clear-cut or high-grade cortical changes) and also of subcortical aberrations, expressed as an increased widening of the third ventricle." | 1.28 | Computed tomography of the brain, hepatotoxic drugs and high alcohol consumption in male alcoholic patients and a random sample from the general male population. ( Mützell, S, 1992) |
| "Seizures and delirium tremens were recorded among 292 randomly selected patients admitted to an in-patient alcoholism program." | 1.27 | Should alcohol withdrawal seizures be treated with anti-epileptic drugs? ( Hillbom, ME; Hjelm-Jäger, M, 1984) |
| " Inter- and intra-subject variation in bioavailability was small (0." | 1.26 | Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. ( Dumbrell, M; Khouw, V; Sandor, P; Sellers, EM, 1981) |
| " prescribing too low a dosage (the average dose in the adult is 5 mg/kg/day) or lack of cooperation by the patient who either takes the drug irregularly or fails to take it at all." | 1.26 | [Determination of plasma phenytoine and treatment of epileptics]. ( De Crousaz, G, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (81.43) | 18.7374 |
| 1990's | 8 (11.43) | 18.2507 |
| 2000's | 2 (2.86) | 29.6817 |
| 2010's | 2 (2.86) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Coralic, Z | 1 |
| Kapur, J | 1 |
| Olson, KR | 1 |
| Chamberlain, JM | 1 |
| Overbeek, D | 1 |
| Silbergleit, R | 1 |
| LaRoche, SM | 1 |
| Shivdat-Nanhoe, R | 1 |
| Blanco-Vidal, MJ | 1 |
| Catalan-Urribarrena, G | 1 |
| Lopez, JI | 1 |
| del Aguila, C | 1 |
| Magnet, A | 1 |
| Pomposo-Gaztelu, I | 1 |
| Montejo, M | 1 |
| ROBERTS, HJ | 1 |
| BAILEY, G | 1 |
| ROSENBAUM, JM | 1 |
| ANDERSON, B | 1 |
| WILHOIT, WM | 1 |
| Jessen, K | 1 |
| Olesen, OV | 1 |
| Halsted, CH | 1 |
| Vasilescu, C | 1 |
| Florescu, A | 1 |
| Esser, J | 1 |
| Brandt, T | 1 |
| Hillbom, ME | 1 |
| Hjelm-Jäger, M | 1 |
| Campbell, WW | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Ritson, B | 1 |
| Coenegracht, JM | 1 |
| Oei, TL | 1 |
| van Breda Vriesman, PJ | 1 |
| Koller, WC | 1 |
| Glatt, SL | 1 |
| Perlik, S | 1 |
| Huckman, MS | 1 |
| Fox, JH | 1 |
| Claus, D | 1 |
| Aschoff, JC | 1 |
| Goldberg, DM | 1 |
| Solomon, JG | 1 |
| Wilker, R | 1 |
| Nathenson, G | 1 |
| Beier, R | 1 |
| Zschiesche, M | 1 |
| Chu, NS | 1 |
| Sandor, P | 1 |
| Sellers, EM | 2 |
| Dumbrell, M | 1 |
| Khouw, V | 1 |
| Aron, DC | 1 |
| Tyrrell, JB | 1 |
| Fitzgerald, PA | 1 |
| Findling, JW | 1 |
| Forsham, PH | 1 |
| Rosich Pla, A | 1 |
| Rathlev, NK | 1 |
| D'Onofrio, G | 1 |
| Fish, SS | 1 |
| Harrison, PM | 1 |
| Bernstein, E | 1 |
| Hossack, RW | 1 |
| Pickens, L | 1 |
| Saitz, R | 1 |
| Friedman, LS | 1 |
| Mayo-Smith, MF | 1 |
| Knoll, B | 1 |
| Haefeli, WE | 1 |
| Ladewig, D | 1 |
| Stohler, R | 1 |
| Fujimoto, K | 1 |
| Nakano, I | 1 |
| Barzilay, D | 1 |
| Orion, E | 1 |
| Brenner, S | 1 |
| Rosenberg, IH | 1 |
| Feldman, RG | 1 |
| Nambara, K | 1 |
| Olbrich, R | 1 |
| Iber, FL | 3 |
| Brzeczko, A | 1 |
| Press, AW | 1 |
| Kirby, S | 1 |
| Cruess, DF | 1 |
| Adir, J | 1 |
| Birkett, DJ | 1 |
| Graham, GG | 1 |
| Chinwah, PM | 1 |
| Wade, DN | 1 |
| Hickie, JB | 1 |
| Josephson, GW | 1 |
| Sabatier, HS | 1 |
| Robertson, CC | 1 |
| De Crousaz, G | 1 |
| Loiseau, P | 1 |
| Brachet, A | 1 |
| Henry, P | 1 |
| Cenraud, P | 1 |
| Vincent, TS | 1 |
| Rodin, EA | 1 |
| Affrime, M | 1 |
| Reidenberg, MM | 1 |
| Mützell, S | 1 |
| Howe, AM | 1 |
| Webster, WS | 1 |
| Lipson, AH | 1 |
| Halliday, JL | 1 |
| Sheffield, LJ | 1 |
| Piepho, R | 1 |
| Whelton, A | 1 |
| Mayor, G | 1 |
| Neu, H | 1 |
| Laddu, A | 1 |
| Heikkinen, ER | 1 |
| Rönty, HS | 1 |
| Tolonen, U | 1 |
| Pyhtinen, J | 1 |
| Welch, RD | 1 |
| Smith, DB | 1 |
| Danosi, SF | 1 |
| Zwanger, ML | 1 |
| Bock, BF | 1 |
| Lucas, D | 2 |
| Pennec, Y | 1 |
| Ménez, JF | 2 |
| Floch, HH | 2 |
| Le Menn, G | 1 |
| Daniel, JY | 1 |
| Bardou, LG | 1 |
| De Matteis, F | 1 |
| Selby, G | 1 |
| Gardner, AJ | 1 |
| Mellor, CS | 1 |
| Kaplan, R | 1 |
| Blume, S | 1 |
| Rosenberg, S | 1 |
| Pitrelli, J | 1 |
| Turner, WJ | 1 |
| Sampliner, R | 1 |
| Frenkel, EP | 1 |
| McCall, MS | 1 |
| Sheehan, RG | 1 |
| Overall, JE | 1 |
| Brown, D | 1 |
| Williams, JD | 1 |
| Neill, LT | 1 |
| Frost, JB | 1 |
| Rothstein, E | 1 |
| Kater, RM | 1 |
| Roggin, G | 1 |
| Tobon, F | 1 |
| Zieve, P | 1 |
| Markkanen, T | 1 |
| Peltola, O | 1 |
| Finer, MJ | 2 |
| Gessner, PK | 1 |
| Madden, JS | 1 |
| Jones, D | 1 |
| Frisch, EP | 2 |
| Kiorboe, E | 1 |
| Glatt, MM | 1 |
| George, HR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Phenobarbital Versus Ativan for Refractory Alcohol Withdrawal Treatment in the Intensive Care Unit[NCT04156464] | Phase 4 | 142 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
7 reviews available for phenytoin and Alcohol Abuse
| Article | Year |
|---|---|
Intestinal absorption and malabsorption of folates.
Topics: Alcoholism; Biological Transport, Active; Celiac Disease; Folic Acid; Folic Acid Antagonists; gamma- | 1980 |
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
The expanding role of microsomal enzyme induction, and its implications for clinical chemistry.
Topics: Acetaminophen; Alcoholism; Animals; Antipyrine; Aryl Hydrocarbon Hydroxylases; Electron Transport; E | 1980 |
[Acquired cortical cerebellar atrophy].
Topics: Alcoholism; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Atrophy; Bromisovalum; Ce | 1999 |
Absorption and malabsorption of folates.
Topics: Alcoholism; Animals; Bile; Biological Transport; Cats; Chickens; Depression, Chemical; Ethanol; Foli | 1976 |
Toxic hepatic porphyrias.
Topics: Alcoholism; Antifungal Agents; Chemical and Drug Induced Liver Injury; Chlorpropamide; Hexachlorocyc | 1968 |
Current trends in Australian neurology.
Topics: Alcoholism; Amino Acids; Aminobutyrates; Animals; Australia; Catecholamines; Central Nervous System; | 1970 |
8 trials available for phenytoin and Alcohol Abuse
| Article | Year |
|---|---|
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures.
Topics: Adult; Alcoholism; Chi-Square Distribution; Double-Blind Method; Ethanol; Female; Humans; Male; Phen | 1994 |
Phenytoin, Metronidazole and multivitamins in the treatment of alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Evaluation Studies as Topic; | 1972 |
Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study.
Topics: Administration, Oral; Alcoholism; Chlordiazepoxide; Clinical Trials as Topic; Drug Evaluation; Elect | 1974 |
Drug treatment of anxiety and depression in detoxified alcoholic patients.
Topics: Alcoholism; Amitriptyline; Analysis of Variance; Anxiety; Ascorbic Acid; Chlordiazepoxide; Depressio | 1973 |
Increased rate of clearance of drugs from the circulation of alcoholics.
Topics: Alcoholism; Clinical Trials as Topic; Ethanol; Humans; Liver; Microsomes; Phenytoin; Tolbutamide; Wa | 1969 |
Phenytoin intoxication during treatment with antabuse (Disulfiram).
Topics: Adult; Alcoholism; Clinical Trials as Topic; Disulfiram; Drug Compounding; Drug Incompatibility; Epi | 1966 |
Evaluation of chlormethiazole in treatment for alcohol withdrawal syndrome. Results of a controlled trial.
Topics: Alcoholism; Chlormethiazole; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Hyp | 1966 |
55 other studies available for phenytoin and Alcohol Abuse
| Article | Year |
|---|---|
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
[Left-sided hemiparesis in a diabetic patient: chronic granulomatous encephalitis due to Acanthamoeba].
Topics: Acanthamoeba; Aged; Alcoholism; Amebiasis; Anti-Infective Agents; Atrial Fibrillation; Biopsy; Brain | 2013 |
THE SYNDROME OF NARCOLEPSY AND DIABETOGENIC (FUNCTIONAL) HYPERINSULINISM. OBSERVATIONS ON 190 PATIENTS, WITH EMPHASIS UPON ITS RELATIONSHIP TO OBESITY, DIABETES MELLITUS AND CEREBRAL DYSRHYTHMIAS.
Topics: Adolescent; Alcoholism; Arrhythmias, Cardiac; Brain; Diabetes Mellitus; Diet; Diet, Reducing; Electr | 1963 |
TOXIC EPIDERMAL NECROLYSIS.
Topics: Alcoholism; Anti-Bacterial Agents; Chloramphenicol; Chlorpromazine; Drug Eruptions; Drug Therapy; Hu | 1965 |
THE BROADER TREATMENT OF ACUTE ALCOHOLISM AND DELIRIUM TREMENS.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Chlorpromazine; Drug Therapy; Humans; Phenytoin; Psychoses, | 1965 |
Recreational use of phenytoin, marijuana, and alcohol: a case report.
Topics: Adult; Alcoholism; Anticonvulsants; Drug Interactions; Humans; Illicit Drugs; Male; Marijuana Abuse; | 2004 |
The influence of disulfiram and calcium carbimide on the serum diphenylhydantoin. Excretion of HPPH in the urine.
Topics: Acetazolamide; Adult; Aged; Alcoholism; Amitriptyline; Chlordiazepoxide; Chlorpromazine; Chromatogra | 1967 |
Peripheral neuropathy with a syndrome of continuous motor unit activity.
Topics: Alcoholism; Electromyography; Humans; Hypesthesia; Male; Middle Aged; Motor Neurons; Neural Conducti | 1982 |
[Pharmacologically-caused eye movement disorders--differential diagnosis and mechanisms of action].
Topics: Alcoholism; Barbiturates; Cerebellar Diseases; Diagnosis, Differential; Eye Movements; Fixation, Ocu | 1983 |
Should alcohol withdrawal seizures be treated with anti-epileptic drugs?
Topics: Adult; Aged; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Carbamazepine; Chlormethiazol | 1984 |
Periodic alternating nystagmus in phenytoin intoxication.
Topics: Alcoholism; Cerebellar Ataxia; Epilepsy, Post-Traumatic; Humans; Male; Middle Aged; Nystagmus, Patho | 1980 |
ABC of alcohol. Help: drugs.
Topics: Alcoholism; Depression; Ethanol; Humans; Phenytoin; Tranquilizing Agents; Vitamins | 1982 |
The influence of bilirubin, alcohol and certain drugs on the kinetics of 99mTc-Diethyl IDA (EHIDA) in humans.
Topics: Alcoholism; Bilirubin; Epilepsy; Ethanol; Humans; Imino Acids; Jaundice; Kinetics; Phenobarbital; Ph | 1983 |
Cerebellar atrophy demonstrated by computed tomography.
Topics: Adult; Alcoholism; Atrophy; Carcinoma; Cerebellar Diseases; Cerebellar Neoplasms; Cerebral Ventricul | 1981 |
Evaluation of infratentorial atrophy by computed tomography.
Topics: Adolescent; Adult; Aged; Alcoholism; Atrophy; Cerebellopontine Angle; Cerebellum; Cerebral Ventricle | 1982 |
Drug interactions on an alcohol unit.
Topics: Adult; Alcoholism; Ataxia; Diagnosis, Differential; Drug Interactions; Epilepsy; Humans; Male; Oxaze | 1982 |
Combined fetal alcohol and hydantoin syndromes.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Alcoholism; Epilepsy; Female; Fetal Alc | 1982 |
[Changed phenytoin kinetics in chronic alcoholism].
Topics: Adult; Alcohol Withdrawal Delirium; Alcoholism; Humans; Kinetics; Male; Middle Aged; Phenytoin; Psyc | 1982 |
Prevention of alcohol withdrawal seizures with phenytoin in rats.
Topics: Acoustic Stimulation; Alcoholism; Animals; Female; Humans; Male; Phenytoin; Rats; Seizures; Substanc | 1981 |
Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.
Topics: Administration, Oral; Adult; Alcoholism; Biological Availability; Ethanol; Humans; Injections, Intra | 1981 |
Cushing's syndrome: problems in diagnosis.
Topics: ACTH Syndrome, Ectopic; Adenoma; Adrenal Cortex Function Tests; Adrenocortical Hyperfunction; Adult; | 1981 |
[Permanent cerebellar degeneration secondary to diphenylhydantoin (author's transl)].
Topics: Adult; Alcoholism; Cerebellar Ataxia; Humans; Male; Phenytoin; Seizures | 1980 |
Alcohol withdrawal: a nationwide survey of inpatient treatment practices.
Topics: Adrenergic beta-Antagonists; Alcoholism; Barbiturates; Benzodiazepines; Chlordiazepoxide; Clonidine; | 1995 |
Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use.
Topics: Adult; Alcoholism; Epilepsy, Generalized; Humans; Male; Methadone; Opioid-Related Disorders; Phenyto | 1997 |
Porphyria cutanea tarda triggered by a combination of three predisposing factors.
Topics: Aged; Alcoholism; Gonadotropin-Releasing Hormone; Humans; Male; Phenytoin; Porphyria Cutanea Tarda; | 2001 |
Patients with epilepsy.
Topics: Affective Symptoms; Age Factors; Alcoholism; Barbiturates; Child; Child, Preschool; Craniocerebral T | 1975 |
[Clinical and experimental studies on the enzymes of liver, small intestinal mucosa and pancreas after chronic ethanol ingestion and anti-epileptic drugs (author's transl)].
Topics: Alcoholism; Animals; Glucaric Acid; Humans; Intestinal Mucosa; Intestine, Small; Liver; Male; NADPH- | 1979 |
Alcohol withdrawal states and the need for treatment.
Topics: Adult; Alcoholism; Chlormethiazole; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Hum | 1979 |
Comparison of steady state phenytoin metabolism in alcoholic immediately after drinking ceases and three weeks later.
Topics: Adult; Alcoholism; Humans; Kinetics; Male; Middle Aged; Phenytoin; Substance Withdrawal Syndrome | 1979 |
Multiple drug interactions with phenytoin.
Topics: Alcoholism; Disulfiram; Epilepsy; Female; Humans; Middle Aged; Phenytoin; Substance Withdrawal Syndr | 1977 |
Rational management of alcohol withdrawal seizures.
Topics: Alcoholism; Anticonvulsants; Humans; Phenytoin; Recurrence; Seizures; Substance Withdrawal Syndrome | 1978 |
Alcohol intoxication and the alcohol withdrawal syndrome.
Topics: Alcoholic Intoxication; Alcoholism; Benzodiazepines; Chlordiazepoxide; Hallucinations; Humans; Pheny | 1978 |
[Determination of plasma phenytoine and treatment of epileptics].
Topics: Alcoholism; Epilepsy; Female; Humans; Male; Patient Compliance; Phenytoin | 1976 |
[Letter: Diphenylhydrantoin poisoning during disulfiram therapy].
Topics: Adult; Alcoholism; Biotransformation; Disulfiram; Enzyme Inhibitors; Epilepsy; Humans; Liver; Male; | 1975 |
Dilantin in the treatment of alcoholism.
Topics: Alcohol Withdrawal Delirium; Alcoholic Intoxication; Alcoholism; Humans; Phenytoin; Substance Withdr | 1975 |
Psychosocial management of patients with complex partial seizures.
Topics: Adult; Alcoholism; Carbamazepine; Delivery of Health Care; Drug Administration Schedule; Epilepsy; E | 1975 |
The protein binding of some drugs in plasma from patients with alcoholic liver disease.
Topics: Alcoholism; Blood Proteins; Chronic Disease; Dapsone; Fluoresceins; Humans; Liver Diseases; Pharmace | 1975 |
Letter: Treatment of ethanol intoxication.
Topics: Alcoholism; Epilepsy; Humans; Phenytoin; Substance Withdrawal Syndrome | 1976 |
Computed tomography of the brain, hepatotoxic drugs and high alcohol consumption in male alcoholic patients and a random sample from the general male population.
Topics: Adult; Aged; Alcoholism; Analgesics; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Antipyrine; Aspiri | 1992 |
Binder's syndrome due to prenatal vitamin K deficiency: a theory of pathogenesis.
Topics: Adolescent; Alcoholism; Aneurysm, Ruptured; Animals; Cartilage; Child, Preschool; Female; Humans; In | 1992 |
Grand mal status epilepticus.
Topics: Alcoholism; Anticonvulsants; Diazepam; Epilepsy, Tonic-Clonic; Ethanol; Humans; Lorazepam; Male; Mid | 1992 |
Development of posttraumatic epilepsy.
Topics: Adolescent; Adult; Aged; Alcoholism; Atrophy; Brain Injuries; Carbamazepine; Cerebral Cortex; Cerebr | 1990 |
Phenytoin loading in chronic alcoholic patients.
Topics: Adult; Alcoholism; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Phenytoin; Protein Bin | 1988 |
Acetaldehyde adducts with serum proteins are not responsible for decreased drug binding in alcoholic patients.
Topics: Acetaldehyde; Adult; Albumins; Alcoholism; Blood Proteins; Diazepam; Female; Humans; Male; Middle Ag | 1986 |
Acetaldehyde adducts with serum proteins: effect on diazepam and phenytoin binding.
Topics: Acetaldehyde; Alcoholism; Binding Sites; Blood Proteins; Diazepam; Ethanol; Humans; In Vitro Techniq | 1986 |
Neuropathy after alcohol withdrawal.
Topics: Adult; Alcoholism; Female; Folic Acid; Humans; Male; Middle Aged; Peripheral Nervous System Diseases | 1972 |
Sedation threshold and sedation recovery time in alcoholics.
Topics: Adult; Alcoholism; Amobarbital; Attention; Chloral Hydrate; Chlorpromazine; Differential Threshold; | 1974 |
Cerebrospinal fluid folate, and vitamin B 12 in anticonvulsant-induced megaloblastosis.
Topics: Aged; Alcoholism; Anemia, Macrocytic; Anemia, Pernicious; Female; Folic Acid; Hematocrit; Hemoglobin | 1973 |
Mesoridazine and chlorpromazine in the treatment of alcohol withdrawal syndrome.
Topics: Administration, Oral; Alcoholism; Chlorpromazine; Female; Humans; Injections, Intramuscular; Male; M | 1973 |
Prevention of alcohol withdrawal seizures: the roles of diphenylhydantoin and chlordiazepoxide.
Topics: Alcoholism; Anticonvulsants; Chlordiazepoxide; Electroencephalography; Ethanol; Humans; Neurons; Phe | 1973 |
Pentose-phosphate pathway of leucocytes.
Topics: Adult; Aged; Alcoholism; Anemia, Aplastic; Arthritis, Rheumatoid; Asthma; Diabetes Mellitus; Female; | 1971 |
Diphenylhydantoin for treatment of alcohol withdrawal syndromes.
Topics: Administration, Oral; Alcoholism; Humans; Phenytoin; Substance Withdrawal Syndrome | 1971 |
Diphenylhydantoin and alcohol withdrawal.
Topics: Alcoholism; Diazepam; Drug Synergism; Humans; Phenytoin; Substance Withdrawal Syndrome | 1971 |
Diphenylhydantoin in alcohol withdrawal.
Topics: Administration, Oral; Alcoholism; Humans; Injections, Intramuscular; Phenytoin; Substance Withdrawal | 1971 |
Chlormethiazole and trifluoperazine in alcohol withdrawal.
Topics: Alcoholism; Chlormethiazole; Coma; Depression; Feeding and Eating Disorders; Female; Headache; Human | 1969 |